Recent Company News

• 01:10 AM ET Oct 08, 2026
  

  Galderma Group announces new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis (CHF 162.60, 0.00)

• 02:01 PM ET Oct 05, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 28-Sep

• 10:37 PM ET Oct 04, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (44 total)

• 11:54 PM ET Oct 01, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (109 total)

• 11:05 PM ET Oct 01, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (75 total)

• 02:57 AM ET Oct 01, 2026
  

  Almirall announces long-term disease control for up to five years in patients with moderate-to-severe atopic dermatitis treated with Lebrikizumab (€10.56, 0.00)

• 01:06 AM ET Oct 01, 2026
  

  Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine (CHF 349.10, 0.00)

• 11:38 PM ET Sep 30, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (25 total)

• 11:09 PM ET Sep 30, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (37 total)

• 06:07 PM ET Sep 30, 2026
  

  Eli Lilly provides detailed results from Phase 3 ACHIEVE-4 trial evaluating efficacy and safety of Foundayo (orforglipron) ($1157.08, 0.00)